AIBT
Aibotics Inc.0.0020
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
881.23KP/E (TTM)
-Basic EPS (TTM)
-0.05Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Aibotics posted a Q2 net loss of $486K, up 3% y/y from $471K, while YTD net loss widened to $1.08M from $897K amid first revenue of $2K. Operating expenses dipped 8% y/y to $361K in Q2, driven by lower product development, yet YTD costs rose 19% on higher consulting and board fees; amortization hit $328K YTD. Cash climbed to $242K from financing inflows of $250K, offsetting $193K operating burn, but total debt swelled to $1.96M across defaulted convertibles at 8-10% rates, with $447K accrued interest. Shares to be issued stand at $2.03M for the 2024 Philon Labs IP buy, amortized over three years. No non-GAAP metrics disclosed in the 10-Q. Yet liquidity strains persist.
10-Q
Q1 FY2025 results
AIBiotics Therapies notched its first revenue of $2,183 in Q1 FY2025 ended March 31, 2025, up from zero a year earlier, yet operating expenses climbed 47% year-over-year to $531,647, driven by higher product development and consulting fees, yielding an operating loss of $529,464 versus $360,872 last year. Net loss widened to $591,397 from $425,942, with the gap mainly from interest expense on defaulted convertible notes totaling $1.1 million principal at 8% effective rates, maturing mostly in 2024. Cash dipped to $156,737 after $28,360 in operating outflows, while liabilities swelled to $5.1 million against scant assets, flagging a $4.9 million working capital deficit. No free cash flow disclosed, as capex stayed nil. Shares outstanding jumped to 45.2 million from 14.9 million, diluting EPS to $(0.01) from $(0.03), with anti-dilution from 1.8 million convertible equivalents excluded. Cash burn slowed quarter-over-quarter. Yet regulatory hurdles in biotech development loom large.
10-K
FY2024 results
AIBotics posted a net loss of $1.8 million for FY2024 ended December 31, 2024, up 56% from $1.2 million in 2023, driven by $1.6 million in general and administrative expenses that swelled 165% year-over-year on $668,000 amortization from the Philon Labs asset buy and higher board pay. No revenue emerged in either year, while interest expense halved to $213,000 amid lower debt discount amortization, though default rates kicked in during Q3. Cash drained to $185,000 from $279,000, with operations burning $259,000 versus $107,000 last year; a $165,000 related-party note provided some financing relief. Yet liquidity strains persist, with $4.9 million current liabilities dwarfing assets. No outlook disclosed. Regulatory hurdles in psychedelics and AI could stall quarterly progress.
8-K
Aibotics signs app dev deal
Aibotics inked a software development deal with GMF Ventures on January 25, 2025, to build iOS and Android apps for its Philbot massage robot, totaling $165,000 in fees. The initial payment came via 500,000 shares of common stock issued to GMF's Steve Fleurimont under the company's equity plan. This bolsters robot accessibility through mobile controls, yet caps contractor liability at fees paid amid strict IP transfer to Aibotics.
AAGH
America Great Health
0.00+0.00
ATAI
Atai Beckley N.V
4.23+0.09
CMPS
COMPASS Pathways Plc - American
6.39-0.20
CYBN
Cybin Inc.
6.66+0.00
ENVB
Enveric Biosciences, Inc.
5.24-0.12
FBLG
FibroBiologics, Inc.
0.24-0.02
HYFT
MindWalk Holdings Corp.
1.68-0.11
IMA
ImageneBio, Inc.
6.25+0.08
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
NRXS
Neuraxis, Inc.
2.70+0.05